Trends can be predicted, and trends can unfold. Here, Liz Beatty – co-founder and chief strategy of Inato – speaks to the beginnings of a new era in drug development brought on by key technological advances in AI.

Historically, large urban academic centres have conducted the majority of clinical trials, leading to such issues as inaccessibility, lack of representation, and intense competition for participants. With growing industry pressure for greater trial access, a more focused effort to bring research into communities is unfolding.

At the same time, there seems little that AI can’t be applied to so as to ameliorate speed and efficacy, and also specificity – and Beatty expands on these points and more.

You can listen to episode 181a of the pharmaphorum podcast in the player below, download the episode to your computer, or find it - and subscribe to the rest of the series - in iTunes, Spotify, Amazon Music, Podbean, and pretty much wherever you get your other podcasts!